Telaglenastat (Inhaled)
Pulmonary Hypertension
PreclinicalActive
Key Facts
About Synhale Therapeutics
Cambridge‑based biotech delivering inhaled small‑molecule therapies for pulmonary hypertension using a proprietary lung‑targeted platform.
View full company profileTherapeutic Areas
Other Pulmonary Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| CAR Liposomes | Vascular Biosciences | Pre-clinical |
| Digital Biomarker for PH | electronRx | Early Development |